Stephanie Dwyer Kaluzna, PharmD, BCCP, discusses atrial fibrillation (AFib) anticoagulation risk stratification, therapy selection, and the emerging role of factor XI/XIa inhibitors.
Stephanie Dwyer Kaluzna, PharmD, BCCP
Advertisement
Stephanie Dwyer Kaluzna, PharmD, BCCP, is clinical assistant professor and cardiology clinical pharmacist at the University of Illinois Chicago Retzky College of Pharmacy.
Articles by Stephanie Dwyer Kaluzna, PharmD, BCCP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
How the Chai Discovery–Eli Lilly Collaboration Could Advance the Future of AI-Driven Biologics Development
2
First-Ever Guideline on Cardio-Kidney-Metabolic Syndrome Calls for Earlier Screening, Coordinated Care
3
Peptide Therapy for Weight Loss: Separating Clinical Promise From Social Media Hype
4
Apixaban vs Rivaroxaban: A Clearer Choice for VTE?
5